Vyleesi Cost in Texas 2026: Prices, Insurance, Medicaid, and Compounded Options

What Is Vyleesi and Why Does Texas Pricing Matter?

Vyleesi is the brand name for bremelanotide, a melanocortin receptor agonist approved by the FDA on June 21, 2019, for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works at MC3R and MC4R receptors in the central nervous system rather than peripherally, which separates it mechanically from hormonal therapies. The FDA label specifies a single 1.75 mg subcutaneous dose no more than once in 24 hours, self-injected approximately 45 minutes before anticipated sexual activity.

Why Pricing Varies So Much in Texas

Texas is the second-most-populous state in the U.S., with more than 30 million residents and a pharmacy field ranging from large chain retailers in Houston and Dallas to rural independent pharmacies in West Texas. That geographic spread alone produces price variation. Beyond geography, the absence of Texas Medicaid coverage and limited commercial formulary placement push most patients toward full cash pay or manufacturer assistance programs, making the effective price highly individual.

HSDD Prevalence Context

HSDD affects an estimated 8 to 10 percent of premenopausal women in the United States, based on epidemiological data reviewed by the FDA Center for Drug Evaluation and Research. Texas alone could have more than one million affected women by population extrapolation, which is why access and cost questions carry real clinical weight.

Vyleesi Cash Price in Texas in 2026

The manufacturer list price for Vyleesi in Texas is approximately $1,200 per month in 2026, consistent with the national wholesale acquisition cost set by Palatin Technologies. GoodRx data and pharmacy benefit analytics consistently show retail sticker prices in that range at major Texas chains including HEB Pharmacy, CVS, and Walgreens.

What "Per Month" Actually Means

Vyleesi is dosed as needed, not daily. The $1,200 figure typically reflects a four-count carton of auto-injectors, which Palatin Technologies packages as a one-month supply based on an average of four sexual encounters per month. Patients who use fewer doses per month do not receive a proportional discount at the pharmacy counter, the carton price is fixed.

Price Variation Across Texas Cities

Cash prices at Texas retail pharmacies in 2026 cluster tightly near the list price because Vyleesi has no generic competition and limited formulary negotiation pressure. Expect $1,150 to $1,250 at Houston, Dallas-Fort Worth, San Antonio, and Austin pharmacies. Rural Texas pharmacies that stock Vyleesi at all typically match or slightly exceed metro pricing due to lower volume.

Does Texas Medicaid Cover Vyleesi?

Texas Medicaid does not cover Vyleesi in 2026. The Texas Medicaid formulary restricts coverage for sexual dysfunction pharmacotherapy to specific type 2 diabetes-related erectile dysfunction treatments for male beneficiaries. HSDD indications for premenopausal women fall outside the covered categories entirely. Texas Health and Human Services Commission publishes the preferred drug list, and bremelanotide does not appear on it.

CHIP and Children's Medicaid

Neither CHIP nor Children's Medicaid covers Vyleesi. The drug is not indicated in pediatric populations, so this is expected.

Medicaid Managed Care Plans in Texas

Texas Medicaid operates primarily through managed care organizations (MCOs) such as UnitedHealthcare Community Plan, Molina Healthcare of Texas, and Superior HealthPlan. All three MCOs mirror the base Texas Medicaid formulary exclusion for bremelanotide. Prior authorization requests submitted to these MCOs for Vyleesi are routinely denied based on the formulary exclusion rather than medical necessity review.

Patients on Texas Medicaid who are diagnosed with HSDD by a licensed provider can pursue the manufacturer savings program if they have any secondary commercial insurance, but dual-eligible patients (Medicaid plus Medicare) face additional constraints because federal anti-kickback rules prohibit applying manufacturer coupons to government-insured prescriptions. The CMS guidance on manufacturer copay assistance reinforces this restriction.

Commercial Insurance Coverage for Vyleesi in Texas

Most commercial health insurance plans sold in Texas in 2026 exclude Vyleesi from their formularies or place it on a non-preferred specialty tier requiring prior authorization that is difficult to satisfy.

Major Texas Employer Plans

Large Texas employers including state government employees covered under the Employees Retirement System (ERS) of Texas generally exclude Vyleesi. The ERS HealthSelect plan's 2026 formulary does not list bremelanotide. Blue Cross and Blue Shield of Texas, the largest commercial insurer in the state, classifies bremelanotide as a non-covered lifestyle drug under most group plans.

Individual and Marketplace Plans

ACA marketplace plans sold in Texas through HealthCare.gov are not required by federal essential health benefit standards to cover HSDD pharmacotherapy. As of 2026, no silver-tier or gold-tier marketplace plan sold in Texas includes bremelanotide on its base formulary. Patients should call the member services number on their insurance card and request a formulary exception in writing if a prescribing clinician documents that Vyleesi is medically necessary.

How to File a Formulary Exception in Texas

Texas requires insurers regulated by the Texas Department of Insurance to respond to formulary exception requests within 72 hours for urgent cases and five business days for standard requests, per Texas Insurance Code Chapter 1369. Submit the request with a Letter of Medical Necessity from your clinician that cites the RECONNECT trial data and the FDA-approved indication. Approval rates for Vyleesi exceptions remain low, but documented medical necessity strengthens any subsequent appeal.

The RECONNECT Trial: Clinical Evidence Underpinning Coverage Decisions

Insurance formulary committees weigh clinical evidence when determining coverage. The RECONNECT trial, the key phase 3 program supporting Vyleesi's FDA approval, enrolled 1,267 premenopausal women across two parallel randomized controlled trials published in Obstetrics and Gynecology in 2019.

Primary Efficacy Findings

Women treated with bremelanotide 1.75 mg showed statistically significant improvements in the Female Sexual Function Index (FSFI) desire domain score compared with placebo (P<0.001). The Decreased Sexual Desire Screener (DSDS) responder rate was 25.0 percent for bremelanotide versus 17.0 percent for placebo in the integrated analysis. The absolute difference is modest, which is part of why many payers classify the drug as providing limited clinical benefit relative to cost.

Safety Profile Relevant to Coverage Discussions

Nausea occurred in 40 percent of bremelanotide-treated patients versus 1 percent of placebo patients in RECONNECT, per the published trial data. Flushing occurred in 20 percent. Transient blood pressure increases averaging 2 mmHg systolic were noted 12 minutes post-dose. The FDA label carries a contraindication for cardiovascular disease, which restricts the eligible patient population and gives some payers additional grounds to require step therapy through non-pharmacological interventions first.

FSFI as a Validated Outcome Measure

The Female Sexual Function Index is a 19-item validated questionnaire used in clinical trials and referenced by the International Society for the Study of Women's Sexual Health (ISSWSH). ISSWSH clinical practice guidelines, available through academic.oup.com, recommend shared decision-making between patient and clinician before initiating bremelanotide, citing the modest effect size alongside the significant nausea burden. Payers frequently cite these same guidelines to justify restrictive formulary placement.

Palatin Technologies Savings Card: How It Works in Texas

Palatin Technologies, the manufacturer of Vyleesi, offers a savings program for commercially insured patients who are not covered by government insurance. Texas residents with commercial insurance may qualify for up to $375 off per fill, reducing out-of-pocket costs per carton to as low as $825 in some scenarios.

Eligibility Requirements

The Palatin savings card is available only to U.S. Residents with commercial insurance coverage. It cannot be used by patients whose primary payer is Medicaid, Medicare, TRICARE, or any other federal or state government health program. Texas patients covered solely by Medicaid are not eligible.

How to Activate the Card

Prescribers or patients can enroll at the Vyleesi manufacturer website. The savings card is presented at the pharmacy at the time of dispensing. The pharmacist applies it as a secondary payment, and the patient pays the reduced copay. Cards typically reset monthly and may have an annual maximum benefit cap, confirm the current cap directly with Palatin's patient support line before relying on it for budgeting.

GoodRx and Third-Party Discount Programs

GoodRx coupons for Vyleesi at Texas pharmacies in 2026 generally do not produce savings below the $1,100 to $1,200 range because the drug lacks generic competition. Third-party discount aggregators like RxSaver and NeedyMeds list Palatin's own program as the primary resource. Patients should compare the Palatin card discount against GoodRx at their specific pharmacy before paying, as pharmacy-specific pricing can create small differences.

Compounded Bremelanotide in Texas: Legality and Cost

Compounded bremelanotide is legal in Texas when prepared by a state-licensed 503A pharmacy operating under the oversight of the Texas State Board of Pharmacy (TSBP). The Texas State Board of Pharmacy enforces USP Chapter 797 sterile compounding standards for injectable preparations, and bremelanotide requires sterile compounding because it is a subcutaneous injection.

503A vs. 503B: The Texas Distinction

A 503A pharmacy compounds for individual patients based on a valid prescription from a licensed Texas prescriber. A 503B outsourcing facility compounds in bulk without patient-specific prescriptions but must register with the FDA under 21 U.S.C. 503B. Bremelanotide is not on the FDA's list of bulk drug substances approved for 503B outsourcing as of 2026, meaning Texans must obtain compounded bremelanotide through a 503A pharmacy with a valid individual prescription.

Cost Comparison: Compounded vs. Brand

Compounded bremelanotide from Texas-licensed 503A pharmacies typically runs approximately $140 per month, representing roughly an 88 percent reduction from the $1,200 brand list price. This price reflects the cost of the active pharmaceutical ingredient, sterile compounding labor, and pharmacy overhead, without the research-and-development premium built into the Vyleesi brand price.

Quality and Safety Considerations

Compounded preparations are not FDA-approved and are not subject to the same pre-market efficacy and safety review as Vyleesi. The FDA's guidance on compounded drugs notes that compounded versions may differ in potency, purity, and sterility from the branded product. Texas patients choosing compounded bremelanotide should verify that their pharmacy holds active TSBP registration and complies with USP 797. Ask for a certificate of analysis from the pharmacy before use.

Finding a Licensed Texas 503A Compounding Pharmacy

The TSBP publishes an online license verification tool at pharmacy.texas.gov. Search by pharmacy name or license number to confirm active licensure and any disciplinary history before filling a compounded bremelanotide prescription.

Telehealth Prescribing of Vyleesi in Texas

Texas law permits telehealth prescribing of Vyleesi to established patients following a legitimate patient-prescriber relationship under Texas Occupations Code Chapter 111. A prescriber licensed in Texas may conduct an audio-visual telehealth visit, complete a medical history including the DSDS or FSFI questionnaire, and issue a bremelanotide prescription electronically to a Texas pharmacy.

What a Telehealth Vyleesi Visit Typically Includes

A HealthRX telehealth visit for HSDD evaluation covers a structured sexual health history, review of contraindications (cardiovascular disease, uncontrolled hypertension, medication interactions with naltrexone), and documentation of the impact of low desire on quality of life. Prescribers will typically also review thyroid function, hormonal status, and psychiatric history because these conditions can mimic or worsen HSDD. The Endocrine Society's clinical practice guidelines recommend ruling out hypogonadism and thyroid dysfunction before initiating bremelanotide.

In-Person vs. Telehealth: Clinical Differences

Telehealth and in-person prescribing carry the same legal obligations in Texas for controlled substances, but bremelanotide is not a scheduled controlled substance. This means DEA special registration requirements for controlled substance telemedicine (under the Ryan Haight Act and its 2023 amendments) do not apply to bremelanotide telehealth visits in Texas. The visit can be fully audio-visual without a prior in-person encounter, provided the prescriber establishes a valid patient-prescriber relationship as defined by the Texas Medical Board.

Drug Interactions and Contraindications Texas Prescribers Must Screen

Before writing a bremelanotide prescription, Texas clinicians must screen for interactions. The FDA label identifies naltrexone as a significant interaction: bremelanotide reduces naltrexone systemic exposure by approximately 35 percent, which is clinically relevant for patients using low-dose naltrexone or naltrexone-bupropion (Contrave) for weight management.

Cardiovascular Contraindications

Women with established cardiovascular disease, including a history of myocardial infarction, stroke, or uncontrolled hypertension, are contraindicated for Vyleesi. The transient blood pressure elevation documented in RECONNECT (mean 2 mmHg systolic at 12 minutes post-dose) may be clinically significant in high-risk patients. Texas telehealth prescribers should collect a blood pressure reading at the time of the initial visit, either via patient self-report with a home monitor or a recent clinic value.

Hyperpigmentation Risk

Bremelanotide may cause focal hyperpigmentation of the face, breasts, and gingiva with repeated dosing, per the FDA label. This effect is more pronounced in patients with darker skin tones. Clinicians should document baseline skin assessment and counsel patients to limit use to no more than one dose per 24 hours and avoid exceeding approximately eight doses per month to reduce cumulative pigmentation risk, based on data from the long-term open-label RECONNECT extension study referenced in Obstet Gynecol 2019.

Comparing Vyleesi to Flibanserin (Addyi) for Texas Patients

Addyi (flibanserin 100 mg oral tablet) is the only other FDA-approved pharmacotherapy for HSDD in premenopausal women. A systematic comparison helps Texas patients and clinicians choose appropriately.

Flibanserin is dosed nightly at bedtime regardless of sexual activity timing. Vyleesi is dosed as needed 45 minutes before anticipated activity. Flibanserin carries a boxed warning for hypotension and syncope with alcohol, a restriction codified under a Risk Evaluation and Mitigation Strategy (REMS) program documented by the FDA. Vyleesi carries no REMS but has the cardiovascular contraindication noted above.

Cost-wise, flibanserin's cash price in Texas runs approximately $800 to $900 per month in 2026, slightly below Vyleesi's list price, but compounded flibanserin is also available at Texas 503A pharmacies for roughly $60 to $90 per month, making it the lower-cost compounded option for patients who tolerate a nightly dosing schedule. A 2021 comparative review in the Journal of Sexual Medicine noted that neither drug produces large absolute improvements in desire scores, and patient preference for on-demand versus daily dosing often drives the prescribing decision.

Practical Cost-Reduction Strategy for Texas Patients

The cheapest legal path to bremelanotide for most uninsured or underinsured Texas patients in 2026 runs through a licensed Texas 503A compounding pharmacy with a telehealth prescription.

Step-by-Step Approach

1. Schedule a telehealth visit with a Texas-licensed prescriber (via HealthRX or another licensed platform) to confirm HSDD diagnosis using validated screening tools such as the DSDS.
2. Confirm the prescriber will send the prescription to a TSBP-licensed 503A compounding pharmacy if the brand price is prohibitive.
3. Verify pharmacy licensure at pharmacy.texas.gov before filling.
4. Request a certificate of analysis confirming active pharmaceutical ingredient potency and sterility.
5. For patients with commercial insurance, apply the Palatin Technologies savings card at a retail pharmacy simultaneously and compare final out-of-pocket cost against the compounded option.

When Brand Vyleesi Is Preferable

Patients who prioritize FDA-approved manufacturing standards, have commercial insurance that covers part of the cost, or who qualify for the full $375 Palatin savings card discount may find the brand product's effective price competitive enough to justify the known quality assurance of a regulated manufacturing site. The FDA's position on compounded versus approved drugs makes clear that approved products carry a safety and efficacy guarantee that compounded preparations do not.